All AbMole products are for research use only, cannot be used for human consumption.
Bempedoic acid (ETC-1002) mediates inhibition of a wide range of proinflammatory molecules that coincides with the modulation of AMPK and MAP kinase activities. It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
In vitro: The phospho-ACC to total-ACC ratio increased by 25% and 60% in cells treated with 50 µM and 100 µM ETC-1002, respectively. Bempedoic acid (ETC-1002) has AMPK-activating properties in primary human MDMs.
In vivo: when mice were treated with 30 mg/kg of Bempedoic acid (ETC-1002) prior to thioglycollate administration, leukocyte influx into the peritoneal cavity was significantly reduced by 48% at 24 h (13.7 × 106/ml lavage fluid; P < 0.008) and by 61% at 72 h (1.8 × 106/ml lavage fluid; P < 0.002)
Biochem Pharmacol. 2025 Feb;232:116721.
The combination of gemcitabine and albumin-bound paclitaxel effectively inhibits de novo lipogenesis in pancreatic cancer cells by targeting the AMPK/SREBP1 pathway
Bempedoic acid (ETC-1002) purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | Primary rat hepatocytes and differentiated human monocyte-derived macrophages |
| Preparation method | Primary rat hepatocytes and differentiated human MDMs are treated with indicated concentrations of ETC-1002 for 12 h. Working solutions of ETC-1002 are prepared in serum-free RPMI 1640 containing 12 mM HEPES, 10,000 U/ml penicillin, and 100 μg/ml streptomycin. |
| Concentrations | 30 μM or 100 μM |
| Incubation time | 12 h |
| Animal Experiment | |
|---|---|
| Animal models | C57BL/6 male mice |
| Formulation | A disodium salt aqueous solution using 2:1 molar ratio of NaOH to ETC-1002 in water containing 0.5% CMC and 0.025% Tween with a final pH 7-8 |
| Dosages | 10 ml/kg |
| Administration | i.p. |
| Molecular Weight | 344.49 |
| Formula | C19H36O5 |
| CAS Number | 738606-46-7 |
| Solubility (25°C) | DMSO 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Nikolic D, et al. Atherosclerosis. ETC-1002: a future option for lipid disorders?
| Related AMPK Products |
|---|
| Dorsomorphin dihydrochloride
Dorsomorphin (BML-275; Compound C) dihydrochloride is a potent inhibitor of AMP-activated protein kinase (AMPK), with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride induces autophagy. |
| OTSSP167
OTSSP167 is a highly potent MELK (maternal embryonic leucine zipper kinase) inhibitor with IC50 of 0.41 nM. |
| WZ4003
WZ4003 is a highly specific NUAK kinase inhibitor with IC50 of 20 nM and 100 nM for NUAK1 and NUAK2, respectively, without significant inhibition on 139 other kinases. |
| Geniposide
Geniposide is an iridoid glycoside isolated from the fruit of Gardenia jasminoides Ellis. |
| Metformin
Metformin (1, 1-dimethylbiguanide) inhibits mitochondrial respiratory chains in the liver, leads to AMPK activation and enhances insulin sensitivity, and can be used in type 2 diabetes research. Metformin can cross the blood-brain barrier and induce autophagy, and Metformin is a CD47 inhibitor in vitro. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
